NASDAQ:TCDA

Tricida (TCDA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.11
$0.19
52-Week Range
N/A
Volume
31.13 million shs
Average Volume
17.62 million shs
Market Capitalization
$6.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TCDA stock logo

About Tricida Stock (NASDAQ:TCDA)

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

TCDA Stock News Headlines

Tricida Inc (TCDAQ)
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Firm Retention Summary: Tricida Inc.
Tricida Announces Third Quarter 2022 Financial Results
Tricida Provides Strategic Update
Why Tricida Stock Is Tanking Today
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Why Is Tricida (TCDA) Stock Down 90% Today?
Tricida announces $125M debt facility - Seeking Alpha
Tricida Whale Trades Spotted
See More Headlines
Receive TCDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
4/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TCDA
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-176,570,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
35,851,000
Market Cap
$6.01 million
Optionable
Not Optionable
Beta
0.22
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Gerrit KlaernerGerrit Klaerner
    President, Chief Executive Officer & Director
  • Geoffrey M. Parker
    Chief Operating & Financial Officer, Executive VP
  • Dawn Parsell
    Executive Vice President-Clinical Development
  • Robert McKague
    Chief Compliance Officer, EVP & General Counsel
  • Annie Yoshiyama
    Chief Accounting Officer & Vice President-Finance

TCDA Stock Analysis - Frequently Asked Questions

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) posted its quarterly earnings data on Monday, November, 8th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by $0.09. During the same quarter in the previous year, the firm posted ($1.55) EPS.

What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida Chief Executive Officer Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among the company's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

Tricida (TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

This page (NASDAQ:TCDA) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners